Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TARIBO: Targeted Therapy +/- Nephrectomy in mRCC
NCT02535351Phase 3Terminated
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Nov 2015
- Primary completion
- Sep 2018
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial (2 arms), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Overall Survival at 5 years. Started Nov 2015; status: terminated.
Beyond the preview
Go deeper on NCT02535351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02535351.